Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | CART19-BE-01: ARI-0001 in CD19+ malignancies

Valentín Ortiz-Maldonado, MD, of the Hospital Clinic, Barcelona, Spain, discusses the initial results of the CART19-BE-01 (NCT03144583), a Phase I multicenter study evaluating ARI-0001, a CD19 targeting chimeric antigen receptor T-cell, in patients with CD19+ relapsed/refractory hematological malignancies. The primary and secondary endpoints of safety and efficacy were met, with an overall survival of 68.6% at one year. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).